The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.
Shares of Danish pharmaceutical giant Novo Nordisk surged close to 14% on Friday after the company announced positive results ...
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...
Novo Nordisk's phase 1b/2a clinical trial results revealed that their investigational drug, amycretin, led to an average ...
Generally, you can count on drugmakers for a steady revenue performance -- since patients need their medicines, revenue holds ...